erlotinib hydrochloride has been researched along with Acute Myelogenous Leukemia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, ZX; Guo, CJ; He, JL; Li, YZ; Peng, C; Peng, F; Song, X; Tan, L; Yu, S; Zhang, RQ | 1 |
| Abou Dalle, I; Alvarado, Y; Borthakur, G; Cortes, JE; Diaz Duque, A; Estrov, Z; Ferrajoli, A; Gandhi, V; Jabbour, E; Kantarjian, HM; Konopleva, M; Lamothe, B; Pemmaraju, N; Pinnamaneni, P; Randhawa, J; Ravandi, F; Wierda, WG | 1 |
| Fenaux, P; Galluzzi, L; Kepp, O; Kroemer, G; Lainey, E; Micol, JB; Sukkurwala, AQ; Wolfromm, A | 1 |
| Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E | 1 |
| Amin, C; Cangany, M; Cripe, LD; Czader, M; Konig, H; Sayar, H | 1 |
| Al-Awar, R; Aman, A; Datti, A; Gronda, M; Hurren, R; Lin, FH; MacLean, N; Minden, MD; Rotin, LE; Schimmer, AD; Wang, X; Wrana, JL | 1 |
| Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Adès, L; Boehrer, S; Bouteloup, C; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Harper, F; Kroemer, G; Lainey, E; Pierron, G; Sébert, M; Tailler, M; Thépot, S | 1 |
| Daub, H; Schreiber, TB; Weber, C | 1 |
| Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A | 1 |
| Bouteloup, C; De Botton, S; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Scoazec, M; Sébert, M; Thépot, S | 1 |
| Chan, G; Pilichowska, M | 1 |
| Adès, L; Boehrer, S; Braun, T; de Botton, S; Fabre, C; Fenaux, P; Galluzzi, L; Gardin, C; Grosjean, J; Kroemer, G; Le Roux, G; Martin, A | 1 |
3 trial(s) available for erlotinib hydrochloride and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Young Adult | 2018 |
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2014 |
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2014 |
13 other study(ies) available for erlotinib hydrochloride and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn.
Topics: Animals; Biomarkers, Tumor; Bone Marrow; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; src-Family Kinases; Tandem Repeat Sequences; THP-1 Cells | 2020 |
EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.
Topics: Antigens, CD34; CD11b Antigen; Cell Cycle Checkpoints; Cell Differentiation; Cholecalciferol; ErbB Receptors; Erlotinib Hydrochloride; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 14; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tretinoin; Tumor Cells, Cultured | 2013 |
Pilot study of erlotinib in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Protein Kinase Inhibitors; Quinazolines | 2015 |
Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.
Topics: Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Ethacridine; Glycoside Hydrolases; Humans; Leukemia, Myeloid, Acute | 2016 |
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed | 2008 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Enzyme Activation; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron; Microscopy, Fluorescence; Microtubule-Associated Proteins; Phosphorylation; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; src-Family Kinases; Stilbenes; TOR Serine-Threonine Kinases | 2011 |
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2012 |
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines | 2012 |
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer.
Topics: Aged; Carcinoma, Small Cell; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2007 |
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Reference Values | 2008 |